BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27910065)

  • 1. Pathology of Endometrial Carcinoma.
    Lax SF
    Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
    Lax SF
    Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular approaches for classifying endometrial carcinoma.
    Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
    Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
    Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
    Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel molecular profiles of endometrial cancer-new light through old windows.
    Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
    Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
    Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
    Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
    Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular carcinogenesis of endometrial cancer.
    Liu FS
    Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathology of endometrial carcinoma.
    Matias-Guiu X; Prat J
    Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma.
    Yoo SH; Park BH; Choi J; Yoo J; Lee SW; Kim YM; Kim KR
    Mod Pathol; 2012 Nov; 25(11):1496-507. PubMed ID: 22766790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.